VIR stock forecast, quote, news & analysis
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer... Show more
Vir Biotechnology (VIR) Stock Analysis: Gilead Deal Sharpens Its Oncology Pipeline
Key Takeaways
- VIR shares traded near $10.79 in mid-October 2026, up roughly 1.8% from a close of $10.60 about 30 days earlier, despite swinging between approximately $9.96 and $11.78 during that stretch.
- On October 14, 2026, Vir announced a multi-program oncology collaboration with Gilead Sciences, featuring up to $135 million in upfront and near-term payments plus up to $1.74 billion in potential milestones.
- The U.S. FDA granted Fast Track designation to VIR-5500, a PSMA-targeted T-cell engager for prostate cancer co-developed with Astellas Pharma.
- The stock has advanced sharply on a year-to-date basis, supported by a growing oncology pipeline and a cash runway into late 2027.
- Key upcoming catalysts include ECLIPSE 1 hepatitis delta topline data expected in the fourth quarter of 2026 and ECLIPSE 2 and 3 data in early 2027.
Current Market Snapshot
Vir Biotechnology shares have been volatile but largely rangebound over the trailing month. After trading near $10.60 in mid-September, the stock climbed to an intraday high near $11.78 in early October before pulling back to a close of $9.96 on October 16, and subsequently recovering toward the $10.79 level. The net 30-day move of roughly 1.8% reflects a market that has been digesting a series of pipeline and partnership headlines rather than re-rating the stock decisively in either direction.
Broader sentiment in clinical-stage biotechnology remains sensitive to funding conditions and data catalysts. Vir has stood out, however, for converting its proprietary PRO-XTEN masking technology into high-value partnerships, which has helped the stock appreciate substantially on a year-to-date basis even as the shares consolidated over the short term.
Vir Biotechnology (VIR) Business Overview and Competitive Position
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on powering the immune system to treat serious infectious diseases and cancer. Its lead clinical program pairs tobevibart, an investigational monoclonal antibody, with elebsiran, an investigational small interfering RNA, for the treatment of chronic hepatitis delta (HDV), a rapidly progressive liver disease with significant unmet need in the U.S. market.
In oncology, Vir is advancing a portfolio of dual-masked T-cell engagers (TCEs) built on its universal PRO-XTEN masking technology, which is designed to keep TCEs inactive until they reach the tumor microenvironment, potentially widening the therapeutic index and enabling less frequent dosing. Lead candidates include VIR-5500 (PSMA), VIR-5818 (HER2), and VIR-5525 (EGFR), targeting validated antigens in solid tumors. The company also operates a preclinical pipeline spanning additional oncology and infectious disease programs.
Recent Developments Driving VIR
The most significant recent catalyst was the October 14, 2026 announcement of a collaboration and license agreement with Gilead Sciences to discover and engineer three novel PRO-XTEN dual-masked TCE candidates for solid tumors. Under the terms, Vir is eligible to receive up to $135 million in upfront and near-term preclinical milestone payments, including $65 million in cash and a $25 million equity investment at a 30% premium, with up to $1.74 billion in further development, regulatory, and commercial milestones plus tiered royalties. The deal combines Vir's T-cell engager discovery, AI-enabled protein engineering, and masking technology with Gilead's oncology development and commercialization expertise.
Separately, on October 8, 2026, Vir announced that the FDA granted Fast Track designation to VIR-5500 for late-line metastatic castration-resistant prostate cancer. VIR-5500 is being co-developed with Astellas Pharma under a global strategic collaboration announced earlier in 2026, which included $335 million in upfront consideration.
On the infectious disease side, Vir's hepatitis delta program remains a central focus, with topline data from the ECLIPSE registrational program expected to begin arriving in the fourth quarter of 2026. Phase II SOLSTICE data have shown deep and durable viral suppression for the tobevibart-elebsiran combination, supporting the company's registrational ambitions in HDV.
Trending AI Robots
Investors tracking momentum in stocks like Vir Biotechnology often turn to quantitative tools for additional context. Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots drawn from a broader universe of hundreds of bots trading thousands of tickers. Only the top-performing and most relevant strategies appear in this section, with each bot differing in trading style, timeframe, and performance metrics. The page offers a way to observe how automated systems are positioning across the market in near real time.
2026 Outlook and What Investors Should Watch
Vir's near-term narrative hinges on the hepatitis delta program, where ECLIPSE 1 topline data is expected in the fourth quarter of 2026, followed by ECLIPSE 2 and ECLIPSE 3 readouts in the first quarter of 2027. These results will be central to assessing the commercial potential of the tobevibart-elebsiran combination and its competitiveness against emerging HDV treatments.
In oncology, investors will monitor dose-escalation data for VIR-5818 (HER2) expected in the second half of 2026, along with further updates across the T-cell engager pipeline and the newly announced Gilead collaboration. Regulatory progress on VIR-5500, ongoing execution with Astellas, and any additional partnership activity tied to the PRO-XTEN platform remain important watchpoints.
Financial positioning also matters: Vir reported roughly $781 million in cash and investments with a runway into the fourth quarter of 2027, providing flexibility ahead of key data readouts. As with all clinical-stage biotechnology companies, trial outcomes, regulatory decisions, competitive developments, and broader biotech financing conditions will continue to drive volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VIR in -6.38% downward trend, sliding for three consecutive days on November 02, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where VIR declined for three days, in 253 of 314 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 51 cases where VIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 75 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for VIR just turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +8.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 203 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
VIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 128 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.932) is normal, around the industry mean (3.104). P/E Ratio (-6.339) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases
Industry Biotechnology